VEGF and pleiotrophin modulate the immune profile of breast cancer

Cancers

Volumn 2, Issue 2, 2010, Pages 970-988

  Lynn, Kristi D ^a   Roland, Christina L ^a   Brekken, Rolf A ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Anti VEGF; Macrophage; Pleiotrophin; VEGF

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; GU 81; PACLITAXEL; PLEIOTROPHIN; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 1 ANTIBODY; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 2 ANTIBODY;

BONE MARROW CELL; BREAST CANCER; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL INFILTRATION; CELL SURVIVAL; COLORECTAL CANCER; DENDRITIC CELL; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOMODULATION; KIDNEY CANCER; KIDNEY CARCINOMA; LEWIS CARCINOMA; MACROPHAGE FUNCTION; MALIGNANT NEOPLASTIC DISEASE; METASTASIS POTENTIAL; MONOTHERAPY; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REGULATORY T LYMPHOCYTE; REVIEW;

EID: 79952267749     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers2020970     Document Type: Review

References (104)

1. American Cancer Society. Cancer Facts and Figures 2009; American Cancer Society: Atlanta, GA, USA, 2009.
2. Tysnes, B.B.; Bjerkvig, R. Cancer initiation and progression: involvement of stem cells and the microenvironment. Biochim. Biophys. Acta 2007, 1775, 283-297.
3. DeNardo, D.G.; Coussens, L.M. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 2007, 9, 212.
4. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285, 1182-1186.
5. Dvorak, H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 2002, 20, 4368-4380.
6. Pradeep, C.R.; Sunila, E.S.; Kuttan, G. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies. Integr. Cancer Ther. 2005, 4, 315-321.
7. Sawano, A.; Iwai, S.; Sakurai, Y.; Ito, M.; Shitara, K.; Nakahata, T.; Shibuya, M. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood 2001, 97, 785-791.
8. Lee, T.H.; Seng, S.; Sekine, M.; Hinton, C.; Fu, Y.; Avraham, H.K.; Avraham, S. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med. 2007, 4, e186.
9. Yang, A.D.; Camp, E.R.; Fan, F.; Shen, L.; Gray, M.J.; Liu, W.; Somcio, R.; Bauer, T.W.; Wu, Y.; Hicklin, D.J.; Ellis, L.M. Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res. 2006, 66, 46-51.
10. Ellis, L.M.; Hicklin, D.J. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin. Cancer Res. 2008, 14, 6371-6375.
11. Grepin, R.; Pages, G. Molecular mechanisms of resistance to tumour anti-angiogenic strategies. J. Oncol. 2010, 2010, 835680.
12. Berardi, A.C.; Wang, A.; Abraham, J.; Scadden, D. T. Basic fibroblast growth factor mediates its effects on committed myeloid progenitors by direct action and has no effect on hematopoietic stem cells. Blood 1995, 86, 2123-2129.
13. Byrd, V.M.; Ballard, D.W.; Miller, G.G.; Thomas, J.W. Fibroblast growth factor-1 (FGF-1) enhances IL-2 production and nuclear translocation of NF-kappaB in FGF receptor-bearing Jurkat T cells. J. Immunol. 1999, 162, 5853-5859.
14. Kitayama, J.; Nagawa, H.; Yasuhara, H.; Tsuno, N.; Kimura, W.; Shibata, Y.; Muto, T. Suppressive effect of basic fibroblast growth factor on transendothelial emigration of CD4(+) T-lymphocyte. Cancer Res. 1994, 54, 4729-4733.
15. Nakayama, T.; Mutsuga, N.; Tosato, G. Effect of fibroblast growth factor 2 on stromal cell-derived factor 1 production by bone marrow stromal cells and hematopoiesis. J. Natl. Cancer Inst. 2007, 99, 223-235.
16. Ribatti, D.; Nico, B.; Vacca, A.; Roncali, L.; Presta, M. Endogenous and exogenous fibroblast growth factor-2 modulate wound healing in the chick embryo chorioallantoic membrane. Angiogenesis 1999, 3, 89-95.
17. Takagi, S.; Takahashi, K.; Katsura, Y.; Matsuoka, T.; Ohsaka, A. Basic fibroblast growth factor modulates the surface expression of effector cell molecules and primes respiratory burst activity in human neutrophils. Acta Haematol. 2000, 103, 78-83.
18. Zhao, X.M.; Citrin, B.S.; Miller, G.G.; Frist, W.H.; Merrill, W.H.; Fischell, T.A.; Atkinson, J.B.; Yeoh, T. K. Association of acidic fibroblast growth factor and untreated low grade rejection with cardiac allograft vasculopathy. Transplantation 1995, 59, 1005-1010.
19. Lewis, C.E.; De Palma, M.; Naldini, L. Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. Cancer Res. 2007, 67, 8429-8432.
20. Lewis, C.E.; Hughes, R. Inflammation and breast cancer. Microenvironmental factors regulating macrophage function in breast tumours: hypoxia and angiopoietin-2. Breast Cancer Res. 2007, 9, 209.
21. Lin, Y.L.; Liang, Y.C.; Chiang, B.L. Placental growth factor down-regulates type 1 T helper immune response by modulating the function of dendritic cells. J. Leukoc. Biol. 2007, 82, 1473-1480.
22. Selvaraj, S.K.; Giri, R.K.; Perelman, N.; Johnson, C.; Malik, P.; Kalra, V.K. Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood 2003, 102, 1515-1524.
23. Burger, J.A.; Kipps, T.J. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006, 107, 1761-1767.
24. Schulz, C.; von Andrian, U.H.; Massberg, S. Hematopoietic stem and progenitor cells: their mobilization and homing to bone marrow and peripheral tissue. Immunol. Res. 2009, 44, 160-168.
25. Perez-Pinera, P.; Chang, Y.; Deuel, T.F. Pleiotrophin, a multifunctional tumor promoter through induction of tumor angiogenesis, remodeling of the tumor microenvironment, and activation of stromal fibroblasts. Cell Cycle 2007, 6, 2877-2883.
26. Lynn, K.D.; Roland, C.L.; Brekken, R.A. Unpulished Data, 2010.
27. Rauvala, H. An 18-kd heparin-binding protein of developing brain that is distinct from fibroblast growth factors. EMBO J. 1989, 8, 2933-2941.
28. Silos-Santiago, I.; Yeh, H.J.; Gurrieri, M.A.; Guillerman, R.P.; Li, Y.S.; Wolf, J.; Snider, W.; Deuel, T.F. Localization of pleiotrophin and its mRNA in subpopulations of neurons and their corresponding axonal tracts suggests important roles in neural-glial interactions during development and in maturity. J. Neurobiol. 1996, 31, 283-296.
29. Vanderwinden, J.M.; Mailleux, P.; Schiffmann, S.N.; Vanderhaeghen, J.J. Cellular distribution of the new growth factor pleiotrophin (HB-GAM) mRNA in developing and adult rat tissues. Anat. Embryol. (Berl.) 1992, 186, 387-406.
30. Yeh, H.J.; He, Y.Y.; Xu, J.; Hsu, C.Y.; Deuel, T.F. Upregulation of pleiotrophin gene expression in developing microvasculature, macrophages, and astrocytes after acute ischemic brain injury. J. Neurosci. 1998, 18, 3699-3707.
31. Courty, J.; Dauchel, M. C.; Caruelle, D.; Perderiset, M.; Barritault, D. Mitogenic properties of a new endothelial cell growth factor related to pleiotrophin. Biochem. Biophys. Res. Commun. 1991, 180, 145-151.
32. Fang, W.; Hartmann, N.; Chow, D.T.; Riegel, A.T.; Wellstein, A. Pleiotrophin stimulates fibroblasts and endothelial and epithelial cells and is expressed in human cancer. J. Biol. Chem. 1992, 267, 25889-25897.
33. Laaroubi, K.; Delbe, J.; Vacherot, F.; Desgranges, P.; Tardieu, M.; Jaye, M.; Barritault, D.; Courty, J. Mitogenic and in vitro angiogenic activity of human recombinant heparin affin regulatory peptide. Growth Factors 1994, 10, 89-98.
34. Milner, P.G.; Li, Y.S.; Hoffman, R.M.; Kodner, C.M.; Siegel, N.R.; Deuel, T.F. A novel 17 kD heparin-binding growth factor (HBGF-8) in bovine uterus: purification and N-terminal amino acid sequence. Biochem. Biophys. Res. Commun. 1989, 165, 1096-1103.
35. Perez-Pinera, P.; Alcantara, S.; Dimitrov, T.; Vega, J.A.; Deuel, T.F. Pleiotrophin disrupts calcium-dependent homophilic cell-cell adhesion and initiates an epithelial-mesenchymal transition. Proc. Natl. Acad. Sci. USA 2006, 103, 17795-17800.
36. Riegel, A.T.; Wellstein, A. The potential role of the heparin-binding growth factor pleiotrophin in breast cancer. Breast Cancer Res. Treat. 1994, 31, 309-314.
37. Choudhuri, R.; Zhang, H.T.; Donnini, S.; Ziche, M.; Bicknell, R. An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res. 1997, 57, 1814-1819.
38. Zhang, N.; Zhong, R.; Wang, Z.Y.; Deuel, T.F. Human breast cancer growth inhibited in vivo by a dominant negative pleiotrophin mutant. J. Biol. Chem. 1997, 272, 16733-16736.
39. Chang, Y.; Zuka, M.; Perez-Pinera, P.; Astudillo, A.; Mortimer, J.; Berenson, J. R.; Deuel, T. F. Secretion of pleiotrophin stimulates breast cancer progression through remodeling of the tumor microenvironment. Proc. Natl. Acad. Sci. USA 2007, 104, 10888-10893.
40. Gerber, H.P.; Malik, A.K.; Solar, G.P.; Sherman, D.; Liang, X.H.; Meng, G.; Hong, K.; Marsters, J.C.; Ferrara, N. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002, 417, 954-958.
41. Robertson, S.; Kennedy, M.; Keller, G. Hematopoietic commitment during embryogenesis. Ann. N. Y. Acad. Sci. 1999, 872, 9-16.
42. Demetri, G.D.; van Oosterom, A.T.; Garrett, C.R.; Blackstein, M.E.; Shah, M.H.; Verweij, J.; McArthur, G.; Judson, I.R.; Heinrich, M.C.; Morgan, J.A.; Desai, J.; Fletcher, C.D.; George, S.; Bello, C.L.; Huang, X.; Baum, C.M.; Casali, P.G. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368, 1329-1338.
43. Motzer, R.J.; Michaelson, M.D.; Rosenberg, J.; Bukowski, R.M.; Curti, B.D.; George, D.J.; Hudes, G.R.; Redman, B.G.; Margolin, K.A.; Wilding, G. Sunitinib efficacy against advanced renal cell carcinoma. J. Urol. 2007, 178, 1883-1887.
44. Nexavar (sorafenib) package insert, 17.5 FDA-approved patient labeling; Bayer Healthcare Pharmaceuticals Inc.: West Haven, CT, USA, 2009.
45. Hooper, A.T.; Butler, J.M.; Nolan, D.J.; Kranz, A.; Iida, K.; Kobayashi, M.; Kopp, H.G.; Shido, K.; Petit, I.; Yanger, K.; James, D.; Witte, L.; Zhu, Z.; Wu, Y.; Pytowski, B.; Rosenwaks, Z.; Mittal, V.; Sato, T.N.; Rafii, S. Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells. Cell Stem Cell 2009, 4, 263-274.
46. Kopp, H.G.; Hooper, A.T.; Avecilla, S.T.; Rafii, S. Functional heterogeneity of the bone marrow vascular niche. Ann. N. Y. Acad. Sci. 2009, 1176, 47-54.
47. Grunewald, M.; Avraham, I.; Dor, Y.; Bachar-Lustig, E.; Itin, A.; Jung, S.; Chimenti, S.; Landsman, L.; Abramovitch, R.; Keshet, E. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 2006, 124, 175-189.
48. Kaplan, R.N.; Riba, R.D.; Zacharoulis, S.; Bramley, A.H.; Vincent, L.; Costa, C.; MacDonald, D.D.; Jin, D.K.; Shido, K.; Kerns, S.A.; Zhu, Z.; Hicklin, D.; Wu, Y.; Port, J.L.; Altorki, N.; Port, E.R.; Ruggero, D.; Shmelkov, S.V.; Jensen, K.K.; Rafii, S.; Lyden, D. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005, 438, 820-827.
49. Tare, R.S.; Oreffo, R.O.; Clarke, N.M.; Roach, H.I. Pleiotrophin/Osteoblast-stimulating factor 1: dissecting its diverse functions in bone formation. J. Bone Miner. Res. 2002, 17, 2009-2020.
50. Vazin, T.; Becker, K.G.; Chen, J.; Spivak, C.E.; Lupica, C.R.; Zhang, Y.; Worden, L.; Freed, W.J. A novel combination of factors, termed SPIE, which promotes dopaminergic neuron differentiation from human embryonic stem cells. PLoS One 2009, 4, e6606.
51. Roger, J.; Brajeul, V.; Thomasseau, S.; Hienola, A.; Sahel, J.A.; Guillonneau, X.; Goureau, O. Involvement of Pleiotrophin in CNTF-mediated differentiation of the late retinal progenitor cells. Dev. Biol. 2006, 298, 527-539.
52. Caruelle, D.; Mazouzi, Z.; Husmann, I.; Delbe, J.; Duchesnay, A.; Gautron, J.; Martelly, I.; Courty, J. Upregulation of HARP during in vitro myogenesis and rat soleus muscle regeneration. J. Muscle Res. Cell Motil. 2004, 25, 45-53.
53. Heiss, C.; Wong, M.L.; Block, V.I.; Lao, D.; Real, W.M.; Yeghiazarians, Y.; Lee, R.J.; Springer, M.L. Pleiotrophin induces nitric oxide dependent migration of endothelial progenitor cells. J. Cell. Physiol. 2008, 215, 366-373.
54. Pollard, J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer. 2004, 4, 71-78.
55. Lin, E.Y.; Li, J.F.; Gnatovskiy, L.; Deng, Y.; Zhu, L.; Grzesik, D.A.; Qian, H.; Xue, X.N.; Pollard, J.W. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 2006, 66, 11238-11246.
56. Allavena, P.; Sica, A.; Garlanda, C.; Mantovani, A. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol. Rev. 2008, 222, 155-161.
57. Zeisberger, S.M.; Odermatt, B.; Marty, C.; Zehnder-Fjallman, A.H.; Ballmer-Hofer, K.; Schwendener, R.A. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br. J. Cancer 2006, 95, 272-281.
58. Lin, E.Y.; Li, J.F.; Bricard, G.; Wang, W.; Deng, Y.; Sellers, R.; Porcelli, S.A.; Pollard, J.W. Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages. Mol. Oncol. 2007, 1, 288-302.
59. Leek, R.D.; Lewis, C.E.; Whitehouse, R.; Greenall, M.; Clarke, J.; Harris, A.L. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 1996, 56, 4625-4629.
60. Leek, R. D.; Harris, A. L. Tumor-associated macrophages in breast cancer. J. Mammary Gland Biol. Neoplasia 2002, 7, 177-189.
61. Qian, B.; Deng, Y.; Im, J.H.; Muschel, R.J.; Zou, Y.; Li, J.; Lang, R.A.; Pollard, J.W. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS One 2009, 4, e6562.
62. Wyckoff, J.B.; Wang, Y.; Lin, E.Y.; Li, J.F.; Goswami, S.; Stanley, E.R.; Segall, J.E.; Pollard, J.W.; Condeelis, J. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 2007, 67, 2649-2656.
63. Dineen, S.P.; Lynn, K.D.; Holloway, S.E.; Miller, A.F.; Sullivan, J.P.; Shames, D.S.; Beck, A.W.; Barnett, C.C.; Fleming, J.B.; Brekken, R.A. Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. Cancer Res. 2008, 68, 4340-4346.
64. Roland, C.L.; Dineen, S.P.; Lynn, K.D.; Sullivan, L.A.; Dellinger, M.T.; Sadegh, L.; Sullivan, J.P.; Shames, D.S.; Brekken, R.A. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol. Cancer Ther. 2009, 8, 1761-1771.
65. Roland, C.L.; Lynn, K.D.; Toombs, J.E.; Dineen, S.P.; Udugamasooriya, D.G.; Brekken, R.A. Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. PLoS One 2009, 4, e7669.
66. Salnikov, A.V.; Heldin, N.E.; Stuhr, L.B.; Wiig, H.; Gerber, H.; Reed, R.K.; Rubin, K. Inhibition of carcinoma cell-derived VEGF reduces inflammatory characteristics in xenograft carcinoma. Int. J. Cancer 2006, 119, 2795-2802.
67. Whitehurst, B.; Flister, M.J.; Bagaitkar, J.; Volk, L.; Bivens, C.M.; Pickett, B.; Castro-Rivera, E.; Brekken, R.A.; Gerard, R.D.; Ran, S. Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model. Int. J. Cancer 2007, 121, 2181-2191.
68. Vroling, L.; Yuana, Y.; Schuurhuis, G.J.; van Hinsbergh, V.W.; Gundy, C.; de Haas, R.; van Cruijsen, H.; Boven, E.; Hoekman, K.; Broxterman, H.J. VEGFR2 expressing circulating (progenitor) cell populations in volunteers and cancer patients. Thromb. Haemost. 2007, 98, 440-450.
69. Chen, H.; Campbell, R.A.; Chang, Y.; Li, M.; Wang, C.S.; Li, J.; Sanchez, E.; Share, M.; Steinberg, J.; Berenson, A.; Shalitin, D.; Zeng, Z.; Gui, D.; Perez-Pinera, P.; Berenson, R. J.; Said, J.; Bonavida, B.; Deuel, T.F.; Berenson, J.R. Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: a novel mechanism of tumor-induced vasculogenesis. Blood 2009, 113, 1992-2002.
70. Sharifi, B.G.; Zeng, Z.; Wang, L.; Song, L.; Chen, H.; Qin, M.; Sierra-Honigmann, M.R.; Wachsmann-Hogiu, S.; Shah, P. K. Pleiotrophin induces transdifferentiation of monocytes into functional endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2006, 26, 1273-1280.
71. Collino, F.; Revelli, A.; Massobrio, M.; Katsaros, D.; Schmitt-Ney, M.; Camussi, G.; Bussolati, B. Epithelial-mesenchymal transition of ovarian tumor cells induces an angiogenic monocyte cell population. Exp. Cell Res. 2009, 315, 2982-2994.
72. Nagaraj, S.; Gabrilovich, D.I. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res. 2008, 68, 2561-2563.
73. Yang, L.; DeBusk, L.M.; Fukuda, K.; Fingleton, B.; Green-Jarvis, B.; Shyr, Y.; Matrisian, L.M.; Carbone, D.P.; Lin, P.C. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004, 6, 409-421.
74. Gabrilovich, D.; Ishida, T.; Oyama, T.; Ran, S.; Kravtsov, V.; Nadaf, S.; Carbone, D. P. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998, 92, 4150-4166.
75. Shojaei, F.; Wu, X.; Malik, A.K.; Zhong, C.; Baldwin, M.E.; Schanz, S.; Fuh, G.; Gerber, H.P.; Ferrara, N. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol. 2007, 25, 911-920.
76. Shojaei, F.; Wu, X.; Zhong, C.; Yu, L.; Liang, X.H.; Yao, J.; Blanchard, D.; Bais, C.; Peale, F.V.; van Bruggen, N.; Ho, C.; Ross, J.; Tan, M.; Carano, R.A.; Meng, Y.G.; Ferrara, N. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 2007, 450, 825-831.
77. Bergers, G.; Brekken, R.; McMahon, G.; Vu, T.H.; Itoh, T.; Tamaki, K.; Tanzawa, K.; Thorpe, P.; Itohara, S.; Werb, Z.; Hanahan, D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2000, 2, 737-744.
78. Nozawa, H.; Chiu, C.; Hanahan, D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc. Natl. Acad. Sci. USA 2006, 103, 12493-12498.
79. Scapini, P.; Morini, M.; Tecchio, C.; Minghelli, S.; Di Carlo, E.; Tanghetti, E.; Albini, A.; Lowell, C.; Berton, G.; Noonan, D.M.; Cassatella, M.A. CXCL1/macrophage inflammatory protein-2-induced angiogenesis in vivo is mediated by neutrophil-derived vascular endothelial growth factor-A. J. Immunol. 2004, 172, 5034-5040.
80. Ancelin, M.; Chollet-Martin, S.; Herve, M.A.; Legrand, C.; El Benna, J.; Perrot-Applanat, M. Vascular endothelial growth factor VEGF189 induces human neutrophil chemotaxis in extravascular tissue via an autocrine amplification mechanism. Lab. Invest. 2004, 84, 502-512.
81. Pahler, J.C.; Tazzyman, S.; Erez, N.; Chen, Y.Y.; Murdoch, C.; Nozawa, H.; Lewis, C.E.; Hanahan, D. Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. Neoplasia 2008, 10, 329-340.
82. Heng, D.Y.; Xie, W.; Regan, M.M.; Warren, M.A.; Golshayan, A.R.; Sahi, C.; Eigl, B.J.; Ruether, J.D.; Cheng, T.; North, S.; Venner, P.; Knox, J.J.; Chi, K.N.; Kollmannsberger, C.; McDermott, D.F.; Oh, W.K.; Atkins, M.B.; Bukowski, R.M.; Rini, B.I.; Choueiri, T.K. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol. 2009, 27, 5794-5799.
83. Ochiai, K.; Muramatsu, H.; Yamamoto, S.; Ando, H.; Muramatsu, T. The role of midkine and pleiotrophin in liver regeneration. Liver Int. 2004, 24, 484-491.
84. Gabrilovich, D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 2004, 4, 941-952.
85. Gabrilovich, D.I.; Chen, H.L.; Girgis, K.R.; Cunningham, H.T.; Meny, G.M.; Nadaf, S.; Kavanaugh, D.; Carbone, D.P. Production of vascular endothelial growth factor by human tumors inhibitis the functional maturation of dendritic cells. Nat. Med. 1996, 2, 1096-1103.
86. Huang, Y.; Chen, X.; Dikov, M.M.; Novitskiy, S.V.; Mosse, C.A.; Yang, L.; Carbone, D.P. Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood 2007, 110, 624-631.
87. Oyama, T.; Ran, S.; Ishida, T.; Nadaf, S.; Kerr, L.; Carbone, D. P.; Gabrilovich, D. I. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J. Immunol. 1998, 160, 1224-1232.
88. Mimura, K.; Kono, K.; Takahashi, A.; Kawaguchi, Y.; Fujii, H. Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2. Cancer Immunol. Immunother. 2007, 56, 761-770.
89. Almand, B.; Resser, J.R.; Lindman, B.; Nadaf, S.; Clark, J.I.; Kwon, E.D.; Carbone, D.P.; Gabrilovich, D.I. Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 2000, 6, 1755-1766.
90. Osada, T.; Chong, G.; Tansik, R.; Hong, T.; Spector, N.; Kumar, R.; Hurwitz, H.I.; Dev, I.; Nixon, A.B.; Lyerly, H.K.; Clay, T.; Morse, M.A. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol. Immunother. 2008, 57, 1115-1124.
91. Fricke, I.; Mirza, N.; Dupont, J.; Lockhart, C.; Jackson, A.; Lee, J.H.; Sosman, J.A.; Gabrilovich, D.I. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin. Cancer Res. 2007, 13, 4840-4848.
92. Hipp, M.M.; Hilf, N.; Walter, S.; Werth, D.; Brauer, K.M.; Radsak, M.P.; Weinschenk, T.; Singh-Jasuja, H.; Brossart, P. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 2008, 111, 5610-5620.
93. van Cruijsen, H.; Hoekman, K.; Stam, A. G.; van den Eertwegh, A. J.; Kuenen, B. C.; Scheper, R. J.; Giaccone, G.; de Gruijl, T. D. Defective differentiation of myeloid and plasmacytoid dendritic cells in advanced cancer patients is not normalized by tyrosine kinase inhibition of the vascular endothelial growth factor receptor. Clin. Dev. Immunol. 2007, 2007, 17315.
94. Dieckmann, D.; Plottner, H.; Berchtold, S.; Berger, T.; Schuler, G. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J. Exp. Med. 2001, 193, 1303-1310.
95. Gupta, S.; Joshi, K.; Wig, J.D.; Arora, S.K. Intratumoral FOXP3 expression in infiltrating breast carcinoma: Its association with clinicopathologic parameters and angiogenesis. Acta Oncol. 2007, 46, 792-797.
96. Donovan, D.; Harmey, J.H.; Toomey, D.; Osborne, D.H.; Redmond, H.P.; Bouchier-Hayes, D.J. TGF beta-1 regulation of VEGF production by breast cancer cells. Ann. Surg. Oncol. 1997, 4, 621-627.
97. Qin, F.X. Dynamic behavior and function of Foxp3+ regulatory T cells in tumor bearing host. Cell Mol. Immunol. 2009, 6, 3-13.
98. Perruche, S.; Zhang, P.; Liu, Y.; Saas, P.; Bluestone, J.A.; Chen, W. CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells. Nat. Med. 2008, 14, 528-535.
99. Cortes-Funes, H. The role of antiangiogenesis therapy: bevacizumab and beyond. Clin. Transl. Oncol. 2009, 11, 349-355.
100. Miller, K.D.; Chap, L.I.; Holmes, F.A.; Cobleigh, M.A.; Marcom, P.K.; Fehrenbacher, L.; Dickler, M.; Overmoyer, B.A.; Reimann, J.D.; Sing, A.P.; Langmuir, V.; Rugo, H.S. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. 2005, 23, 792-799.
101. Miller, K.; Wang, M.; Gralow, J.; Dickler, M.; Cobleigh, M.; Perez, E.A.; Shenkier, T.; Cella, D.; Davidson, N.E. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 2007, 357, 2666-2676.
102. Schneider, B.P.; Wang, M.; Radovich, M.; Sledge, G.W.; Badve, S.; Thor, A.; Flockhart, D.A.; Hancock, B.; Davidson, N.; Gralow, J.; Dickler, M.; Perez, E.A.; Cobleigh, M.; Shenkier, T.; Edgerton, S.; Miller, K.D. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J. Clin. Oncol. 2008, 26, 4672-4678.
103. Ko, J.S.; Zea, A.H.; Rini, B.I.; Ireland, J.L.; Elson, P.; Cohen, P.; Golshayan, A.; Rayman, P.A.; Wood, L.; Garcia, J.; Dreicer, R.; Bukowski, R.; Finke, J.H. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 2009, 15, 2148-2157.
104. Connolly, D.T.; Heuvelman, D.M.; Nelson, R.; Olander, J.V.; Eppley, B.L.; Delfino, J.J.; Siegel, N.R.; Leimgruber, R.M.; Feder, J. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J. Clin. Invest. 1989, 84, 1470-1478.